Seeking Alpha
27 Sept 2026, 14:44 UTC · 1h ago
Verdict
Source says Buy. We score UTHR +0.80 across three claims.
Score confirms the headline.
Buy
Rating stated in the headline
+0.80strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
United Therapeutics is facing FDA reviews for Idiopathic Pulmonary Fibrosis (IPF) and Ralinepag.
Priced inanalysis of known catalysts
So whatPositive outcomes for these two pipelines would provide the non-Tyvaso growth required to justify the analyst's $535 price target.
More positive than 93% of claims this week
The company's revenue has declined for two consecutive quarters due to competition from Liquidia's Yutrepia.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced indiscussion of previous quarterly results
So whatThis trend has already driven the stock down ~19% from its $609.35 52-week high.
More negative than 85% of claims this week
Revenue declines are isolated to older formulations, while the Tyvaso DPI product continues to grow.
Priced inanalysis of existing product performance
So whatMaintaining DPI growth is the primary hedge against the erosion of legacy revenue streams in the next print.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The analyst maintains a 'Buy' rating with a high price target, arguing that recent revenue declines are isolated and upcoming FDA reviews provide significant upside.
More positive than 76% of ticker scores this week
Mentioned as a competitor whose product Yutrepia is driving revenue declines for United Therapeutics, implying a gain in market share.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
4h ago
—
UTHR hasn't traded since this ran. Last close $475.45 (Sep 25); the reaction starts at the next open.
UTHR chart →
